REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
REGN on Nasdaq
Shares outstanding
104,986,330
Price per share
$749.44
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
88,738,990
Total reported value
$68,499,969,524
% of total 13F portfolios
0.03%
Share change
+2,128,828
Value change
+$1,958,094,566
Number of holders
1,353
Price from insider filings
$749.44
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JPMORGAN CHASE & CO 4.4% -14% $2,729,989,170 -$462,704,633 4,742,611 -14% JPMORGAN CHASE & CO. 30 May 2025
FMR LLC 3.2% -55% $1,880,548,739 -$2,703,197,470 3,359,563 -59% FMR LLC 30 Jun 2025

As of 31 Dec 2025, 1,353 institutional investors reported holding 88,738,990 shares of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN). This represents 85% of the company’s total 104,986,330 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN) together control 56% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.6% 9,075,153 +0.3% 0.1% $7,004,838,346
BlackRock, Inc. 8.3% 8,741,270 -1.1% 0.11% $6,747,123,706
STATE STREET CORP 4.4% 4,660,808 -0.65% 0.12% $3,597,537,871
Dodge & Cox 4.4% 4,596,358 +1% 1.9% $3,547,790,849
JPMORGAN CHASE & CO 3.8% 3,940,160 -3.2% 0.2% $3,041,292,891
FRANKLIN RESOURCES INC 2.4% 2,560,004 +4.4% 0.49% $1,975,990,279
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,519,540 -0.65% 0.12% $1,936,711,198
FMR LLC 2.2% 2,319,566 +20% 0.09% $1,790,403,167
Nuveen, LLC 1.9% 2,010,517 +71% 0.41% $1,551,857,756
PRICE T ROWE ASSOCIATES INC /MD/ 1.9% 1,949,797 +142% 0.16% $1,504,991,000
LOOMIS SAYLES & CO L P 1.8% 1,934,326 -2.3% 1.8% $1,493,048,247
Invesco Ltd. 1.5% 1,591,105 +7.2% 0.19% $1,228,126,594
Capital World Investors 1.3% 1,398,003 -30% 0.15% $1,079,077,052
MORGAN STANLEY 1.3% 1,389,323 -4.2% 0.06% $1,072,379,189
NORGES BANK 1.2% 1,311,485 0.11% $1,012,295,927
BANK OF AMERICA CORP /DE/ 1.1% 1,157,426 +0.3% 0.06% $893,382,732
GOLDMAN SACHS GROUP INC 1% 1,097,099 +15% 0.12% $846,817,812
AQR CAPITAL MANAGEMENT LLC 0.95% 995,710 +38% 0.4% $768,518,494
NORTHERN TRUST CORP 0.9% 944,933 -4% 0.09% $729,365,434
Amundi 0.75% 791,906 +27% 0.19% $611,248,483
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.74% 778,001 +3% 0.09% $600,515,632
Bank of New York Mellon Corp 0.73% 764,242 +14% 0.1% $589,896,126
DEUTSCHE BANK AG\ 0.73% 763,926 +9.7% 0.19% $589,651,560
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 0.71% 745,233 +0.14% 0.12% $575,222,995
Legal & General Group Plc 0.71% 743,027 -3.5% 0.13% $573,520,247

Institutional Holders of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 88,738,990 $68,499,969,524 +$1,958,094,566 $771.87 1,353
2025 Q3 86,996,223 $48,932,877,141 -$1,211,088,841 $562.27 1,235
2025 Q2 89,209,869 $46,858,212,368 -$1,426,702,234 $525.00 1,192
2025 Q1 92,030,457 $58,330,479,204 -$1,189,685,324 $634.23 1,275
2024 Q4 93,286,684 $66,492,644,189 -$479,615,848 $712.33 1,299
2024 Q3 92,775,414 $97,325,332,836 -$1,389,777,813 $1051.24 1,377
2024 Q2 94,041,724 $98,807,158,234 +$1,312,660,088 $1051.03 1,326
2024 Q1 92,759,471 $89,156,855,451 +$2,508,878,899 $962.49 1,301
2023 Q4 91,348,974 $80,250,681,450 +$167,710,733 $878.29 1,264
2023 Q3 91,165,414 $75,038,056,657 -$525,679,317 $822.96 1,169
2023 Q2 91,953,885 $66,140,528,710 -$553,052,249 $718.54 1,156
2023 Q1 92,595,818 $76,020,982,589 +$89,011,870 $821.67 1,182
2022 Q4 92,696,176 $66,864,723,638 -$266,120,511 $721.49 1,147
2022 Q3 92,906,259 $64,040,087,013 -$168,708,759 $688.87 1,066
2022 Q2 93,068,613 $55,019,554,470 +$640,020,015 $591.13 1,053
2022 Q1 92,282,918 $64,432,639,590 +$1,537,895,341 $698.42 1,082
2021 Q4 90,102,844 $56,873,192,901 +$52,711,404 $631.52 1,065
2021 Q3 90,013,397 $54,432,928,676 +$779,583,867 $605.18 1,008
2021 Q2 88,855,592 $49,577,081,270 -$361,559,165 $558.54 959
2021 Q1 89,440,318 $42,282,450,124 -$390,555,615 $473.14 906
2020 Q4 90,316,473 $43,589,271,335 -$890,178,034 $483.11 892
2020 Q3 91,983,733 $51,497,235,324 -$511,019,782 $559.78 899
2020 Q2 92,590,578 $57,723,182,729 +$10,927,851,201 $623.65 923
2020 Q1 75,018,948 $36,621,954,337 +$962,200,288 $488.29 802
2019 Q4 73,748,017 $27,687,657,792 +$214,177,689 $375.48 686
2019 Q3 73,531,027 $20,397,221,917 -$56,344,089 $277.40 615
2019 Q2 73,672,018 $23,050,091,718 -$88,569,727 $313.00 649
2019 Q1 73,893,704 $30,322,408,939 +$403,604,659 $410.62 703
2018 Q4 73,180,451 $27,332,195,171 -$157,698,682 $373.50 658
2018 Q3 73,586,468 $29,729,310,651 +$467,693,099 $404.04 631
2018 Q2 72,541,663 $25,025,110,595 +$77,686,718 $344.99 611
2018 Q1 72,288,934 $24,889,114,663 +$217,451,545 $344.36 610
2017 Q4 71,399,076 $26,844,190,218 -$489,810,414 $375.96 627
2017 Q3 72,344,472 $32,340,696,308 -$332,091,791 $447.12 598
2017 Q2 73,000,243 $35,847,977,289 +$1,272,746,514 $491.14 593
2017 Q1 71,894,137 $27,857,921,756 +$2,362,709,719 $387.51 570
2016 Q4 71,764,033 $26,345,990,159 -$641,633,351 $367.09 570
2016 Q3 73,533,826 $29,548,540,482 +$474,492,825 $402.02 546
2016 Q2 72,453,964 $25,316,735,783 -$80,452,734 $349.23 533
2016 Q1 72,548,546 $26,150,397,007 -$309,874,125 $360.44 539
2015 Q4 73,174,000 $39,723,882,129 -$79,287,903 $542.87 572
2015 Q3 73,229,090 $34,060,430,264 -$210,641,854 $465.14 553
2015 Q2 73,811,559 $37,655,809,796 +$414,401,121 $510.13 536
2015 Q1 72,958,000 $32,934,634,624 +$441,453,646 $451.48 504
2014 Q4 72,038,036 $29,554,336,522 +$161,167,975 $410.25 506
2014 Q3 71,645,964 $25,826,003,495 -$604,408,877 $360.52 471
2014 Q2 73,368,344 $20,726,843,276 -$36,098,810 $282.47 444
2014 Q1 73,402,366 $22,037,080,841 -$740,153,368 $300.28 448